£2.2M
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
Oxford Drug Design
Oxford Drug Design develops novel cancer therapeutics using a proprietary computational and machine learning platform.
£4.4MTotal raised
Oxford Drug Design is a biotechnology company that uses a proprietary computational and machine learning platform to discover small-molecule drugs for oncology. The firm originated as a spinout from Oxford University.
Filed accounts
Net current assets
Members only
Total assets less current liabilities
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Current assets
Members only
Employees
Members only
Cash, assets and headcount from Oxford Drug Design's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
PF
Paul Finn
CEO
Paul brings extensive drug design and research experience from leadership roles at Oxford Drug Design, InhibOx, and TopoTarget A/S. He also serves as a professorial research fellow at the University of Buckingham.
LinkedInGR
Graham Richards
Professor
Graham brings scientific and academic experience from the University of Oxford, alongside founding and chairing roles across multiple life sciences and technology ventures.
LinkedIn
Alan Roth
CEO
Alan is chief executive officer at Oxford Drug Design and managing director at Fitzroy Partners Limited. He previously served as co-founder and first CEO, CFO at Chiral Quest, and as a director at Commerzbank Asset Management.
LinkedInInvestors
- £2.2M
- £2.2M
Funding history
£2.2M
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.